Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
14. Mai 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
11. Mai 2021 16:17 ET
|
Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in...
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
04. Mai 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
28. April 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy to Present at the Needham Virtual Healthcare Conference
06. April 2021 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01. August 2019 16:20 ET
|
Otonomy, Inc.
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
25. Juli 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
12. Juni 2019 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
06. Mai 2019 16:17 ET
|
Otonomy, Inc.
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial in Ménière’s disease on...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
02. Mai 2019 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...